Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Lucira Health, Inc. (LHDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.86000.0000 (0.00%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.8600
Open1.8400
Bid1.7700 x 2200
Ask1.9600 x 1000
Day's Range1.8095 - 1.9200
52 Week Range1.3600 - 11.1000
Volume38,480
Avg. Volume89,942
Market Cap72.958M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.8930
Earnings DateNov 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
  • Motley Fool

    Lucira Health, Inc. (LHDX) Q1 2022 Earnings Call Transcript

    Earlier today, Lucira Health released financial results for the first quarter ended March 31, 2022. Joining me on today's call are Erik Engelson, president and chief executive officer; and Dan George, chief financial officer.

  • GlobeNewswire

    Lucira Health Announces First Quarter 2022 Results and Business Update

    EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results and provided business updates for the first quarter ended March 31, 2022. Recent Highlights Achieved net revenue of $90.5 million for the first quarter of 2022, equivalent to 97% of fiscal year 20

  • MarketWatch

    Lucira Health files for FDA authorization of first COVID-19 & flu at-home molecular test

    Lucira Health Inc. said Thursday it has filed for Food and Drug Administration authorization for its first-of-its-kind COVID-19 & flu at-home molecular test. The medical tech company, which went public in February of 2021, specializes in single-use test kits for respiratory diseases. "The request is for prescription at-home use of the PCR-quality test for those with suspected COVID-19 or Influenza," the company said in a statement. The company is hoping to get authorized ahead of the fall and wi

Advertisement
Advertisement